David, there is another thread for IGT Subject 13462
This release is from Feb 99
IGT PHARMA STARTS HUMAN TRIAL WITH
ANHYDROVINBLASTINE (AVLB) FOR THE TREATMENT
OF LUNG CANCER
Management is pleased to announce that the first patient has been
treated with IGT's new drug, Anhydrovinblastine. The clinical trial
is a Phase I study for the use of Anhydrovinblastine in the treatment
of advanced solid tumors including non-small cell lung cancer.
This is a single center, open label, non-randomized Phase 1 study.
This study will be conducted at the Roswell Park Cancer Institute
in Buffalo, New York and will assess the safety and tolerability of
Anhydrovinblastine in these patients.
The study will enroll up to 30 patients with advanced solid
cancers. The clinical trial will determine the maximum tolerated
dose (MTD) and the dose limiting toxicities (DLT) of AVLB on an
escalating dose basis. The clinical investigators will assess the
safety profile of AVLB, establish the recommended dose schedule
for future Phase 2 trials, determine drug kinetics and look for
evidence of antitumor activity.
Roswell Park Cancer Institute is a division of the New York State
Department of Health and a National Cancer Institute Designated
Comprehensive Cancer Center. Roswell Park is the nation's first
cancer research, treatment and education center and the third
largest. Roswell Park brings together on one campus a staff of
2,700, including over 200 physicians, and senior scientists,
oncology nurses, allied health professionals and lab technicians,
all devoted to cancer care and research.
IGT is also pleased to announce the appointment of Gary N.
Schwartz, M.D., to the Oncology Advisory Committee. Dr.
Schwartz is a graduate from Stanford University School of
Medicine. He is currently a clinical oncologist at the Department
of Solid Tumor Oncology and Investigational Therapeutics,
Division of Medicine, Roswell Park Cancer Institute. Dr.
Schwartz is also the Assistant Professor of Medicine, State
University of New York. His experience in clinical oncology and
investigational drugs will bring further depth to IGT's cancer drug
development programs.
IGT Pharma is a Vancouver based bio-pharmaceutical drug
discovery company focused on the development of innovative
solutions to target cancer and diseases of the central nervous
system.
On behalf of the board of directors of IGT Pharma Inc. |
